Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer

Critical Reviews in Oncology/Hematology

Volumn 32, Issue 2, 1999, Pages 105-112

  Lachaine, Jean ^a   Laurier, Claudine ^a   Langleben, Adrian ^b   Vaillant, Linda ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; QUALITY OF LIFE; VOMITING;

EID: 0032752294     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00025-6     Document Type: Article

References (21)

1. Coates A., Abraham S., Kaye S. et al. On the receiving end - patient perception of the side effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 19:1983;203-208.
2. Penta J., Poster D., Bruno S. The pharmacological treatment of nausea and vomiting caused by cancer chemotherapy. Laszlo J. Antiemetics and cancer chemotherapy. 1983;53-92 Williams & Wilkins, Baltimore.
3. Lindley C.M., Bernard S., Fields A.M. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J. Clin. Oncol. 7(8):1989;1142-1149.
4. Markham A., Sorkin E. Ondansetron, an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs. 45(6):1993;931-952.
5. Buxton M.J., O'Brien B.J. Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br. J. Cancer. 66:1992;S64-S67.
6. Cunningham D., Gore M., Davidson N. et al. The real cost of emesis - An economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur. J. Cancer. 29A(3):1993;303-306.
7. Sands R., Roberts J.T., Marsh M. et al. Low dose ondansetron and dexamethasone: a cost-effective alternative to high dose metoclopramide/dexamethasone/lorazepam in the prevention of acute cisplatin induced emesis. Clin. Oncol. 4:1992;67-68.
8. Johnson N.E., Nash D.B., Carpenter C.E. et al. Ondansetron, cost and resource utilisation in a US teaching hospital setting. Pharmacoecon. 3(6):1993;471-481.
9. Zbrozek A.S., Cantor S.B., Cardenas M.P. et al. Pharmaoceconmic analysis of ondansetron versus metoclopramide for cisplatin induced nausea and vomiting. Am. J. Hosp. Pharm. 51:1994;1555-1563.
10. Cox F., Hirsch J. Ondansetron: a cost-effective advance in antiemetic therapy. Oncology. 50:1993;186-190.
11. O'Brien B. Economic evaluation of pharmaceuticals. Frankenstein monster or vampire of trials? Med. Care. 34(Suppl. 12):1996;DS99-DS108.
12. Cochran W.G., Cox G.M. Experimental designs. 2nd edition:1957;Wiley, New York.
13. Campora E., Giudici S., Merlini L., Rubagotti A., Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am. J. Clin. Oncol. 17(6):1994;522-526.
14. du Bois A., McKenna C.J., Andersson H., Lahousen M., Kitchener H., Pinter T., Capstick V., Wilkinson J.R. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. Oncology. 54(1):1997;7-14.
15. Jorgensen M., Victor M.A. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Acta Oncol. 35(2):1996;159-163.
16. Soukop M., McQuade B., Hunter E., Stewart A., Kaye S., Cassidy J., Kerr D., Khanna S., Smyth J., Coleman R. et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 49(4):1992;295-304.
17. Aaronson N.K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in International clinical trials in oncology. J. Natl. Cancer Inst. 85(5):1993;365-376.
18. Fayers P, Aaronson N, Bjordal K, Sullivan M. EORTC QLQ-C30, Scoring manual. EORTC Quality of Life Study Group: Brussels; 1995.
19. Osoba D., Zee B., Warr D. et al. Quality of life studies in chemotherapy induced emesis. Oncology. 53(Suppl. 1):1996;92-95.
20. Dicato M.A., Kaasa S., Campora E. et al. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis. A randomized, single blind, multicenter study. Clin. Oncol. 4:1992;275-279.
21. Brown G.H., Paes D., Bryson J. et al. The effectiveness of a single intravenous dose of ondansetron. Oncology. 49:1992;273-278.